The CU Technology Transfer Office (TTO) announced that two new patents have been issued for work by CU researchers.
The research group is led by V. Michael Holers of the CU School of Medicine, Rheumatology. One patent is for novel anti-Factor B antibodies.
This patent is part of a portfolio of intellectual property covering compounds that can be used to reduce or prevent airway hyper-responsiveness and airway inflammation, making them potential treatments for diseases such as asthma and chronic obstructive pulmonary disease (COPD). This IP portfolio is the basis for a drug currently in early-stage clinical trials.
TTO began pursuing this family of patents in February 2004; in addition to five related U.S. patents, patent protection is also granted or pending in Europe, China and several other regions. The patent (U.S. 8,652,475, “Inhibition of Factor B, the Alternative Complement Pathway and Methods Related Thereto”) was issued on Feb. 24, 2014.
In addition to Holers, other inventors on this patent include Joshua Thurman (SOM, Renal Medicine) and Erwin Gelfand (SOM, Pediatrics; National Jewish Health) as well as additional collaborators from National Jewish Health (Christian Taube) and the Medical University of South Carolina.
A second patent also has been issued from this intellectual property portfolio: U.S. 8,703,140 (same title as above). This patent covers additional aspects of these compounds, which also can be used as potential treatments for diseases such as asthma and COPD. As noted above, this IP portfolio is the basis for a drug currently in early-stage clinical trials.